Overall, no significant association was found between CYP1B1 Asn453Ser polymorphism and colorectal cancer susceptibility (dominant model: OR = 0.97, 95% CI = 0.87–1.08, Ph = 0.053, I2 = 49.6%; recessive model: OR = 0.92, 95% CI = 0.76–1.11, Ph = 0.617, I2 = 0.0%; homozygote model: OR = 0.92, 95% CI = 0.76–1.11, Ph = 0.685, I2 = 0.0%; heterozygote model: OR = 0.97, 95% CI = 0.86–1.11, Ph = 0.016, I2 = 61.8%; additive model: OR = 0.97, 95% CI = 0.91–1.03, Ph = 0.135, I2 = 38.6%). This evidence concerns the gene CYP1B1 and colorectal cancer.